Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AXL | P30530 | 1/20 | 0.34 |
| ▸ | TRPV1 | Q8NER1 | 5/20 | 0.33 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.32 |
| ▸ | NOS1 | P29475 | 1/20 | 0.31 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24089313 | 0.87 | — | — | |
| SCHEMBL22924131 | 0.71 | — | — | |
| SCHEMBL18408609 | 0.70 | — | — | |
| SCHEMBL21938210 | 0.70 | IDO1 (0.38) | AXLTRPA1NOS1 | |
| SCHEMBL17030759 | 0.69 | IDO1 (0.41) | AXLTRPA1NOS1 | |
| SCHEMBL25724223 | 0.68 | MAPT (0.33) | — | |
| SCHEMBL21734001 | 0.67 | NOS1 (0.32) | NOS1 | |
| SCHEMBL24285781 | 0.66 | IDO1 (0.34) | AXLTRPV1TRPA1NOS1 | |
| SCHEMBL20858119 | 0.66 | TRPV1 (0.35) | AXLTRPV1TRPA1 | |
| SCHEMBL20858102 | 0.66 | HCAR2 (0.32) | TRPA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10696655-B2 | Therapeutic compounds and uses thereof | GENENTECH, INC. (US) | 2020-06-30 | — | — | US | disclosed |
| US-20190152949-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2019-05-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190152949-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | EP300, HDAC1, HDAC11 | AXL 4482/4885TRPV1 1737/4885TRPA1 2938/4885 |
| US-10696655-B2 | Therapeutic compounds and uses thereof | EP300, HDAC1, HDAC11 | AXL 4482/4885TRPV1 1737/4885TRPA1 2938/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.